AstraZeneca plc (ADR) (AZN)
$45.29
-1.09 (-2.35%)
| CAPS Rating |
|
|---|---|
| Open | $44.62 |
| Previous Close | $46.38 |
| Daily Range | $44.60 - $45.53 |
| 52-Week Range | $29.96 - $47.61 |
| Market Cap | $65.58B |
| P/E Ratio | 10.81 |
| Dividend (Yield) | 2.09 (4.50%) |
| Volume | 1,262,510 |
| Average Daily Volume | 1,390,000 |
AZN
VS S&P 500 (SPY)
How do you think AZN will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AZN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AZN News and Commentary
- Dubai Jitters Rattle Drug Stocks; QLT Gains – SmartMoney
- A Mostly Meaningless FDA Approval – The Motley Fool
- This Baby Is a Nice Addition – The Motley Fool
- Eli Lilly To Pay $2 Million Cash Severance To Retiring R&D Chief – SmartMoney
- AstraZeneca Files Brilinta New Drug Application With FDA – SmartMoney
- UPDATE: FDA Panel Votes Against Approving Xolair In Children – SmartMoney
- Your Heart or Your Stomach? – The Motley Fool
- Drug Lowers Cholesterol; Stock Follows – The Motley Fool
- FDA Panel Questions Dosing Levels For Novartis's Xolair – SmartMoney
- UPDATE: Crestor Cuts Cardiovascular Problems In Women – SmartMoney
- AstraZeneca's Crestor Cuts Cardiovascular Problems In Women – SmartMoney
- UPDATE: FDA Warns Doctors On Using Plavix With Heartburn Meds – SmartMoney
- 3 Stocks With 25% Sales Growth – SmartMoney
- UPDATE: Icahn Reports New Stakes In Genzyme, Forest Labs – SmartMoney
- US HHS has not learned from H1N1 mistakes-senators – Reuters
- Music to Health-Care Investors' Ears – The Motley Fool
- Abbott Puts a Nail in Merck's Coffin – The Motley Fool
- Proposed AstraZeneca Anticlotting Drug Better Than Plavix:Study – SmartMoney
- Abbott: Brave or Stupid? – The Motley Fool
- AstraZeneca Research Chief Lundberg To Join Eli Lilly – SmartMoney
RSS Headlines
Fool UK
